Ret Proto-Oncogene antibody (C-Term)
Quick Overview for Ret Proto-Oncogene antibody (C-Term) (ABIN2744030)
Target
See all Ret Proto-Oncogene (RET) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Specificity
- Recognizes endogenous levels of RET protein.
-
Purification
- Immunoaffinity purified
-
Immunogen
-
KLH-conjugated synthetic peptide encompassing a sequence within the C-terminal region of human RET.
Type of Immunogen: Synthetic peptide
-
-
-
-
Application Notes
- Approved: ICC (1:100 - 1:500), IF, IHC, IHC-P (1:100 - 1:200), WB (1:500 - 1:1000)
-
Comment
-
Target Species of Antibody: Human
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- Lot specific
-
Buffer
- PBS, pH 7.3, 0.01 % sodium azide, 30 % glycerol.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Aliquot to avoid freeze/thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot to avoid freeze/thaw cycles.
-
-
- Ret Proto-Oncogene (RET)
-
Alternative Name
- RET
-
Background
-
Name/Gene ID: RET
Subfamily: Cadherin
Family: Protein Kinase
Synonyms: RET, Cadherin family member 12, CDHF12, C-ret, Hirschsprung disease 1, HSCR1, Hydroxyaryl-protein kinase, Oncogene ret, Proto-oncogene c-Ret, RET-ELE1, RET51, Ret proto-oncogene, RET transforming sequence, RET43, Men2-ret, MEN2B, MTC1, Receptor tyrosine kinase, CDHR16, MEN2A, PTC, RET9 -
Gene ID
- 5979
-
Pathways
- RTK Signaling, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation
Target
-